fbpx Skip to main content

A retrospective study led by Dr. Victoria Silver at Louisiana State University, Health Sciences Center in New Orleans analyzed how race and asthma influence COVID-19 outcomes. The study began around the time that Louisiana was deemed to have the fastest-growing COVID-19 outbreak worldwide. Dr. Silver’s work recognizes the disproportionate number of COVID-19-related deaths of Black people that have occurred since in Louisiana and throughout the country. 

The study was composed of 249 female and male participants, with a median age of 59 years old. Approximately 87% of the participants were Black, and 86% were 65 years old or older or had one or more additional medical conditions. The participants were all patients of an urban safety-net hospital and tertiary care academic medical center in New Orleans and had reactive SARS-CoV-2 testing in March 2020. 

The study ultimately found that Black patients had a significantly longer duration of COVID-19 symptoms at presentation (p < 0.005). This finding is suggestive of increased SARS-CoV-2 exposure and potential barriers in accessing primary care, consistent with longstanding structural violence and institutional racism. Black patients were also found to be significantly more likely to have asthma (p = 0.008).  

Worse outcomes were associated not with race but with patient age and initial oxygen requirement. Black patients were not found to be sicker on presentation than non-Black patients. However, Black patients were found to be significantly overrepresented in COVID-19-related hospitalizations relative to the overall population, making up 87% of cases. The hospital’s typical census of Black patients prior to the COVID-19 pandemic was 55%. 

You May Also Like::  Probiotic Assemblage in Allergic Rhinitis

The study concluded that Black patients were significantly more likely to have asthma, longer duration of COVID-19 symptoms at presentation, and disproportionate representation in COVID-19-related hospitalizations. A call to action is made advocating for the development of COVID-19 prevention programs for Black communities. Such an intervention might help to reduce asthma and COVID-19-related racial inequities and hospitalizations, protecting and saving more Black lives [1]. 

Source:

[1] Victoria Silver, Andrew G Chapple, Allison H Feibus, Jeremy Beckford, Natalie A Halapin, Delphi Barua, Angellica Gordon, Will Baumgartner, Seth Vignes, Cullen Clark, Sanjay Kamboj, Stephen C Lim, Scott P Mackey, Paula S Seal, Joseph M Kanter, Caryn Bell, Meredith E Clement (2020). Clinical Characteristics and Outcomes Based on Race of Hospitalized Patients With COVID-19 in a New Orleans Cohort. Open Forum Infectious Diseases, 7(9). https://doi.org/10.1093/ofid/ofaa339

 

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.

#dermtwitter
@AADmember

New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More